These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35738803)

  • 1. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
    Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.
    Jinno S; Onishi A; Dubreuil M; Akashi K; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J; Morinobu A
    Rheumatol Int; 2020 Dec; 40(12):1987-1995. PubMed ID: 32728836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs.
    Ozen G; Pedro S; England BR; Mehta B; Wolfe F; Michaud K
    ACR Open Rheumatol; 2019 Sep; 1(7):424-432. PubMed ID: 31777822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
    Tageldin M; Wilson N; Yin Y; Sharma TS
    Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.
    Song YK; Lee J; Jo J; Kwon JW
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
    Ranza R; de la Vega MC; Laurindo IMM; Gómez MG; Titton DC; Kakehasi AM; Brigante A; Benitez A; Ranzolin A; Granel A; Cappuccio AM; Quinteros A; Hayata ALS; Smichowski A; Duarte ÂLBP; Kahlow BS; Andia CS; Brenol CV; Velozo E; Mussano E; Soriano ER; Christopoulos GB; da Rocha Castelar Pinheiro G; de Castro GRW; Casado G; da Silveira Carvalho HM; Exeni IE; da Silveira IG; Petkovic I; Pereira IA; da Costa IP; Rosa JE; Miranda JRS; de Moraes JCB; Bertolo MB; Buhl M; Lázaro MA; da Sauma MFLC; de Medeiros Pinheiro M; Díaz M; de Vechi MVSS; Cerda OL; Astesana P; Curi PF; Louzada-Jr P; Teodoro RB; Toledo RA; Papasidero S; Valim V; Fernandes V; Saurit V; Bianchi WA; ; de Melo Costa Pinto R; Descalzo MA; Gomez-Reino JJ
    Clin Rheumatol; 2019 Aug; 38(8):2129-2139. PubMed ID: 31016578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.